Αρχική World News Longest Follow-Up for ICI Plus TKI Favours Treatment with Avelumab Plus Axitinib... World News Longest Follow-Up for ICI Plus TKI Favours Treatment with Avelumab Plus Axitinib Combination versus Sunitinib in Patients with Advanced RCC Από Ogkologos - 11 Φεβρουαρίου, 2025 1062 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a final analysis of the JAVELIN Renal 101 study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR ctDNA Analysis is Feasible for Detection of Minimal Residual Disease After... 2 Ιουλίου, 2021 Assessment of Patients’ Perspective on the Consequences of the COVID-19 Pandemic... 16 Ιουλίου, 2020 TMB Consortium Develops a TMB Calibration Tool 13 Οκτωβρίου, 2021 Genetic Risk Score Increases Prediction of Severe Obesity in Adult Survivors... 5 Αυγούστου, 2022 Φόρτωση περισσοτέρων HOT NEWS Olaparib after Initial Treatment Delays Ovarian Cancer Progression Predictive Performance of DNA Methylation-based Test in Combination with HPV16/18 Genotyping... Neoadjuvant Nivolumab Plus Ipilimumab Leads to a Pathological Response in a... Multipronged Approach Eliminates Racial Disparities in Early-Stage Lung Cancer Treatment